

INDEX

(January-December 1961)

Ad
l
i

Ad
f
i
Ad

Ag

Air
c

c

Aki

Alc

Am

Am

Ana

Ana

a

f

p

t

Ana

a

h

si

A

- Adenoma
 bronchial, *April*, 29
 incidence in solitary pulmonary nodules, *April*, 7 ff., 11, 29
- Adrenal steroids
 for shock, *Oct.*, 38
 in ulcerative colitis, *Sept.*, 23 ff.
- Adrenocorticotrophic hormone, in ulcerative colitis, *Sept.*, 23 f.
- Aging, premature, testicular disorders in, *March*, 29
- Airway
 expiratory resistance, *May*, 23 f.
 increase in, causing dyspnea, *May*, 10, 23 ff.
- obstruction
 causing dyspnea, *May*, 6, 10, 23 f.
 in comatose patient, *Aug.*, 15 (major), causes and treatment, *May*, 27 ff.
- Akinesia, in Parkinsonism, *Jan.*, 14 ff.
- Alcoholism, acute, coma in, *Aug.*, 28
- Amebiasis, diagnosis, *Sept.*, 15
- Amphetamines, as stimulants, *Nov.*, 28 f.
- Anaphylaxis, shock in, *Oct.*, 34
- Androgens
 adrenal, *March*, 8 f.
 for hypogonadism, *March*, 32 ff.
 physiologic effects, *March*, 8 f.
- testicular
 catabolism of, *March*, 8
 deficiency of, and male climacteric, *March*, 29
 deficiency of, manifestations, *March*, 16 ff.
 effect of malnutrition on, *March*, 26
 metabolic pathway for, *March*, 6 f.
 precursors of, *March*, 6 f.
- Anemia
 aplastic, clostridial shock in, *Oct.*, 26
 hemolytic
 in sickle cell hemoglobin diseases, *Feb.*, 19 f.
 in thalassemia major, *Feb.*, 32
 sickle cell
 haptoglobins in, *Feb.*, 22 f.

- hemoglobin structure in, *Feb.*, 9, 10
 with other hemoglobinopathies, *Feb.*, 16 f.
 pathology, *Feb.*, 24 f.
 physiologic and clinical considerations, *Feb.*, 16 ff., 31
 thalassemia with, *Feb.*, 30, 31
 treatment, *Feb.*, 34 f.
- Anorchie, congenital, *March*, 17
- Anoxia, causing Parkinsonism, *Jan.*, 25
- Antibiotic therapy
 anaphylactic shock in, *Oct.*, 34
 in infectious shock, *Oct.*, 35 f.
 in ulcerative colitis, *Sept.*, 22
- Antihistamines, in Parkinsonism, *Jan.*, 32
- Anxiety
 chronic forms, *Nov.*, 10 f.
 clinical diagnosis, *Nov.*, 7 ff.
 factor in suicide, *July*, 18 f.
 tranquilizers in, *July*, 31; *Nov.*, 13 ff.
 versus tranquillity, *Nov.*, 6, 11 f.
- Aphasia, global, *Aug.*, 13
- Arteriosclerosis, causing Parkinsonism, *Jan.*, 6, 24
- Arthralgia, in bronchial carcinoma, *April*, 14
- Arthritis, degenerative, differentiated from Parkinsonism, *Jan.*, 30
- Asthma
 bronchial, ventilatory impairment in, *May*, 24
 "cardiac," *May*, 44
- Atelectasis, causing "lung shunt," *May*, 38 f.
- Atropine
 intoxication, *Aug.*, 29
 for Parkinsonism, *Jan.*, 31

B

- Bacteria
 endotoxins of, in shock, *Oct.*, 7 ff., 19 ff.
 intestinal, in hemorrhagic shock, *Oct.*, 10
 see also specific bacterial infections
- Barbiturates
 avoidance in suicidal patients, *July*, 32

- Barbiturates—(Cont.)
 for colitis patients, *Sept.*, 23
 producing coma, *Aug.*, 28 f.
 in tachycardia episode, *Dec.*, 17
- Barium enema, in ulcerative colitis, *Sept.*, 14
 contraindications, *Sept.*, 11
- Behavior
 impulsive, and risk of suicide, *July*, 17
 patterns increasing suicide risk, *July*, 20 f.
- Benztropine methanesulfonate, for Parkinsonism, *Jan.*, 32
- Biopsy
 aspiration, in pulmonary nodule, *April*, 17
 scalene node, in pulmonary nodule diagnosis, *April*, 17
 of solitary pulmonary nodule (total), *April*, 22
- Blepharospasm, in Parkinsonism, *Jan.*, 22
- Blood
 cerebral flow in metabolic disorders, *Aug.*, 9
 circulation failure, and shock, *Oct.*, 6, 11, 13
 diseases, clostridial septicemia in, *Oct.*, 26
 hemoglobins in normal red cells, *Feb.*, 8
 "shunt"
 hepatic, causing encephalopathy, *Aug.*, 24 f.
 pulmonary, causing hypoxemia, *May*, 38 f.
 volume alterations in shock, *Oct.*, 8, 9
- Blood transfusion
 causing gram-negative infection with shock, *Oct.*, 21
 in hemoglobin diseases, *Feb.*, 34 f.
 in serum hepatitis transmission, *June*, 4, 17, 29 f.
 in shock, *Oct.*, 37
- Brain
 cerebral cortex and consciousness, *Aug.*, 6, 8
 electrical activity at levels of consciousness, *Aug.*, 4 f.
 failure, coma as, *Aug.*, 8 f.
- intracranial infection, coma in, *Aug.*, 23
 metabolism, *Aug.*, 9
 organic disease
 causing coma, *Aug.*, 11, 20 f.
 depression with, *July*, 9
 severe trauma, diagnosis and treatment, *Aug.*, 21 ff.
 stem, and consciousness, *Aug.*, 6 f.
 vascular disorders, *Aug.*, 20 f.
- Breathing
 decreased capacity
 increased ventilatory demand causing, *May*, 31
 obstructive ventilatory impairment causing, *May*, 23 ff.
 restrictive ventilatory impairment causing, *May*, 14 ff.
 difficult. *See* Dyspnea
 exercises, in emphysema, *May*, 28
 mechanics of, *May*, 12 ff.
 normal ventilation, *May*, 31
 positive-pressure, in emphysema, *May*, 28, 29
 reserve, *May*, 4, 45
- Bronchodilators, in obstructive emphysema, *May*, 27, 28
- Bronchography, in diagnosis of pulmonary nodule, *April*, 17
- Bronchoscopy, in diagnosis of pulmonary nodule, *April*, 17
- C
 Calcification, in solitary pulmonary nodules, *April*, 4, 5, 21 f.
 Candidiasis, shock in, *Oct.*, 32
 Carbon monoxide intoxication, and Parkinsonism, *Jan.*, 25
 Carcinoma, in ulcerative colitis, *Sept.*, 8 f.
 Carcinoma, bronchial
 resections for, *April*, 22 f., 28 f.
 in solitary nodules
 cell types in, *April*, 25 f.
 delay in surgery, and survival, *April*, 27 f.
 incidence, *April*, 6 ff., 24 f.
 postoperative survival, *April*, 25 f.
 symptoms in, *April*, 13 f.
 and survival, *April*, 26 f.

- thoracotomy in diagnosis, *April*, 22
- Cardiopulmonary disease
advancing to coma, *Aug.*, 23 f.
treatment of dyspnea in, *May*, 32, 33
- Cardiovascular disease, in sickle cell hemoglobin disorders, *Feb.*, 20
- Carotid sinus stimulation
in atrial flutter, *Dec.*, 29 f.
cautions in use, *Dec.*, 15
effect on various tachycardias, *Dec.*, 13
in paroxysmal atrial fibrillation, *Dec.*, 22
in paroxysmal atrial tachycardia with block, *Dec.*, 34
in sinus tachycardia, *Dec.*, 6
technic, *Dec.*, 12 ff.
in ventricular tachycardia, *Dec.*, 39
- Cellulitis
gram-negative, and shock, *Oct.*, 21
streptococcal, causing shock, *Oct.*, 30
- Chemicals
causing Parkinsonism, *Jan.*, 25
coma-producing, *Aug.*, 27 f.
noxious, and testicular dysfunction, *March*, 30 ff.
- Chlordiazepoxide, as tranquilizer, *Nov.*, 21
- Cholera
fluid therapy in, *Oct.*, 37
pathogenesis of shock in, *Oct.*, 11
- Chromatin pattern
female pattern in males, *March*, 18
in Klinefelter's syndrome, *March*, 19
- Chromosome number, in seminiferous-tubule-dysgenesis, *March*, 19
- Climacteric, male, *March*, 29
- Clostridial infections, shock in, *Oct.*, 12 f., 24 ff.
- Coccidioidomycosis, in solitary pulmonary nodule, *April*, 33
- Cogwheel phenomenon, in Parkinsonism, *Jan.*, 18, 22
- "Coin lesion," *April*, 4
- Colectomy, in ulcerative colitis, *Sept.*, 24, 25 f.
- Colitis, ulcerative
definitions of extent, *Sept.*, 5 f.
diagnostic procedures in, *Sept.*, 12 ff.
differential diagnosis, *Sept.*, 15 ff.
etiology and pathology, *Sept.*, 7 f.
fulminant, surgery in, *Sept.*, 18
historical data, *Sept.*, 6
incidence, *Sept.*, 7
familial, *Sept.*, 7
laboratory data in, *Sept.*, 12 f.
pregnancy and, *Sept.*, 26
prognosis, *Sept.*, 27 f.
surgery in, *Sept.*, 24, 25 f.
symptoms and signs, *Sept.*, 9 ff.
of severe illness, *Sept.*, 11
treatment, *Sept.*, 18 ff.
- Colon
familial polyposis differentiated from colitis, *Sept.*, 17
perforation in ulcerative colitis, *Sept.*, 11
hormone therapy masking, *Sept.*, 23
spastic, *Sept.*, 15
tuberculous involvement, *Sept.*, 17
- Coma
as brain failure, *Aug.*, 8 f.
conditions simulating, *Aug.*, 10 ff.
defined, *Aug.*, 4
examination of patient, *Aug.*, 16 ff.
general management of patient, *Aug.*, 14 ff.
major causes, *Aug.*, 10 f.
diagnosis and treatment, *Aug.*, 20 ff.
progression from consciousness to, *Aug.*, 4 ff.
- Commissurotomy, mitral, atrial fibrillation after, *Dec.*, 27
- Consciousness
levels of, *Aug.*, 4 ff.
mechanisms of loss, *Aug.*, 3 ff.
- Cor pulmonale, acute, in ventilatory insufficiency, *May*, 17 f.
- Craniopharyngioma, causing panhypopituitarism, *March*, 23

Crohn's disease, *Sept.*, 6, 16
 Cryptorchism
 etiology and management, *March*,
 20 f.
 in Laurence-Moon-Biedl syn-
 drome, *March*, 27
 due to testicular hyperpyrexia,
 March, 20
 Cycrimine, for Parkinsonism, *Jan.*,
 31
 Cyst, bronchogenic, as solitary nod-
 ule, *April*, 7, 8 f., 10, 35
 Cystoscopy, infectious shock follow-
 ing, *Oct.*, 19 f.

D

Deanol, as stimulant, *Nov.*, 28
 Delirium, preceding coma, *Aug.*, 8
 f.
 Depression
 diagnosis, *July*, 6 ff.; *Nov.*, 24
 differentiated from Parkinsonism,
 Jan., 30
 drug therapy in, *July*, 30; *Nov.*,
 22 ff., 27, 29
 electroconvulsive therapy in, *July*,
 35
 nosology, *July*, 7
 physical symptoms, *July*, 9 ff.
 Dextroamphetamine, for depressive
 states, *July*, 30
 Diabetes mellitus, hypoglycemic co-
 ma in, *Aug.*, 15, 25
 Diarrhea
 drug control of, *Sept.*, 22
 of infections, fluid therapy in,
 Oct., 37
 nervous, *Sept.*, 15
 see also Colitis, ulcerative
 Diet, in ulcerative colitis, *Sept.*, 19
 f.
 Digitalis
 for atrial fibrillation, *Dec.*, 23 f.
 for atrial flutter, *Dec.*, 30 f.
 for heart failure with shock, *Oct.*,
 39
 in paroxysmal atrial tachycardia,
 Dec., 17, 19
 toxicity, in atrial tachycardia
 with block, *Dec.*, 32 f., 34 f.
 Diphenylmethane derivatives, as
 tranquilizers, *Nov.*, 21
 Diphtheria, circulatory collapse in,
 Oct., 14 f.

Diverticulitis, differentiated from
 ulcerative colitis, *Sept.*, 16
 Dreams, indicating suicide danger,
 July, 22
 Drugs
 causing testicular dysfunction,
 March, 30 ff.
 coma-producing, *Aug.*, 27 ff.
 hypersensitivity suggesting infec-
 tious shock, *Oct.*, 34
 intoxication, depression in, *July*,
 9
 in paroxysmal atrial tachycardia,
 Dec., 17 ff.
 psychoactive, *Nov.*, 5 ff.
 see also Antibiotic therapy, spe-
 cific categories and agents
 Dysentery, bacillary, differentiated
 from colitis, *Sept.*, 16

Dyspnea
 causes of
 classification, *May*, 9 ff.
 experimental studies of, *May*, 7
 f.
 hyperventilation, *May*, 31 ff.
 increased ventilatory demand,
 May, 30
 obstructive ventilatory impair-
 ment, *May*, 23 ff.
 restrictive ventilatory impair-
 ment, *May*, 14 ff.
 experimental studies of, *May*, 7
 ff.
 index, *May*, 4
 mechanisms of, in emphysema,
 May, 25 ff.
 sensations associated with, *May*,
 6 f.
 as subjective symptom, *May*, 3
 ff.

E

Electric countershock, in ventricu-
 lar tachycardia, *Dec.*, 42
 Electrocardiogram
 in atrial fibrillation, *Dec.*, 22
 in atrial flutter, *Dec.*, 30
 in atrial tachycardia with block,
 Dec., 33
 in sinus tachycardia, *Dec.*, 6, 7
 in various tachycardias, *Dec.*, 10
 in ventricular tachycardia, *Dec.*,
 39

Electroconvulsive therapy, for suicidal patients, *July*, 35

Electrolyte, derangement causing coma, *Aug.*, 26 f.

Emotional disorders

in Parkinsonism, *Jan.*, 19 f., 23, 26

treatment, *Jan.*, 34 f.

psychoactive drugs in, *Nov.*, 5 ff.
see also Anxiety, Depression

Emotions, relation to ulcerative colitis, *Sept.*, 8, 21

Emphysema, chronic obstructive mechanism of dyspnea in, *May*, 24 ff.

treatment of, *May*, 28 ff.

Encephalitis, epidemic, and Parkinsonism, *Jan.*, 6, 20 ff.

Enteritis

clostridial, *Oct.*, 26 f., 29

regional, *Sept.*, 16

staphylococcal, *Oct.*, 26 f., 28 f.

Enterocolitis, pseudomembranous clostridial, *Oct.*, 27

staphylococcal, *Oct.*, 14

Epidemics, viral hepatitis, *June*, 9, 19

Epididymis, obstruction of, *March*, 21 f.

Epilepsy, psychomotor, and coma, *Aug.*, 14

Erythrocytes

in sickle cell anemia, *Feb.*, 22

sickling phenomenon, *Feb.*, 17

in thalassemia, *Feb.*, 29, 32

Estrogens

effects on testicular function, *March*, 25 f.

testis synthesizing, *March*, 8

Ethopropazine, for Parkinsonism, *Jan.*, 32

Etryptamine, as stimulant, *Nov.*, 29

Eunuchoidism, *March*, 28

Extrapryramidal disorders, surgical treatment, *Jan.*, 35 f.

Eyes

abnormalities in sickle cell disease, *Feb.*, 25

motor manifestations of Parkinsonism, *Jan.*, 18, 22 f.

F

Face "masking," in Parkinsonism, *Jan.*, 15

Fatigue, chronic, stimulants in therapy, *Nov.*, 22, 23 f.

Fertility

and cryptorchism, *March*, 20

impaired

with ductal obstruction, *March*, 21 f.

after mumps orchitis, *March*, 22

Fever, hemorrhagic, shock in, *Oct.*, 17, 37

Fibrillation

atrial, *Dec.*, 20 ff.

after atrial flutter, *Dec.*, 31 f.
ventricular, *Dec.*, 43

Fistula, arteriovenous, in pulmonary nodule, *April*, 15

Fluid therapy

in infectious shock, *Oct.*, 36 f.

in liver failure, *Aug.*, 25

Flutter, atrial, *Dec.*, 28 ff.

Food poisoning, staphylococcal, *Oct.*, 13, 28, 37

Fungus infections, shock in, *Oct.*, 18, 32

G

Gait, in Parkinsonism, *Jan.*, 14, 17, 24, 29

Gamma globulin, in viral hepatitis, *June*, 24, 29, 30

Gas gangrene, clostridial shock in, *Oct.*, 12, 24 f.

Glycerol derivatives, as tranquilizers, *Nov.*, 19 f.

Gonadotrophins

deficiency of, in hypogonadism, *March*, 23 ff.

urinary, normal value in male, *March*, 15

Gonads, male

morphology, *March*, 3 ff.

normal laboratory values of function, *March*, 15

physiologic considerations, *March*, 6 ff.

Granuloma

etiology of, *April*, 33 f.

pulmonary

incidence in solitary nodules, *April*, 7 f., 10, 32

multiple, alveolar-capillary block in, *May*, 35 f.

H

- Hamartoma, in solitary pulmonary nodules, *April*, 7 f., 9 f., 34
- Handwriting, in Parkinsonism, *Jan.*, 17
- Haptoglobins
normal level, *Feb.*, 23
in sickle cell anemia, *Feb.*, 22 f.
- Head injury, causing coma, *Aug.*, 11, 21 f.
- Heart
arrhythmias. *See* specific conditions
cardiac tamponade complicating infection, *Oct.*, 33
disease
dyspnea in, *May*, 44
tachycardias with, *Dec.*, 5, 9 f., 20, 28, 36
failure
in ventilatory insufficiency, *May*, 18, 19 f.
treatment in emphysema, *May*, 29
first sound, in tachycardias, *Dec.*, 6, 10 f., 21, 33, 37
massage (closed chest), *Dec.*, 43
- Hemodialysis, in severe drug poisoning, *Aug.*, 28
- Hemoglobinopathies, *Feb.*, 3 ff.
comparative, clinical findings in, *Feb.*, 31
see also Hemoglobins, abnormal
- Hemoglobins
A₂
in adult (normal), *Feb.*, 8
in thalassemia minor, *Feb.*, 29
abnormal
chemical structure, *Feb.*, 9 ff.
genotypes of, *Feb.*, 12 f.
hemoglobin M disease, *Feb.*, 27 f.
hemoglobins C, D and E causing disease, *Feb.*, 26 f., 31
rare types of, *Feb.*, 6, 27
with sickle cell trait, *Feb.*, 16 f.
sickling phenomenon, *Feb.*, 16 ff.
in thalassemia disorders, *Feb.*, 30
treatment of disorders, *Feb.*, 33 ff.

- electrophoretic characteristics of, *Feb.*, 5
- fetal
in adult (normal), *Feb.*, 8
in thalassemia major, *Feb.*, 30
fingerprint patterns of peptides of, *Feb.*, 8 f.
inheritance of, *Feb.*, 3, 11 ff.
nomenclature system for, *Feb.*, 5
normal
chemical structure, *Feb.*, 7 ff.
in erythrocytes of adult, *Feb.*, 8
polypeptides associated in, *Feb.*, 13 f.
- Hemophilus infection, shock in, *Oct.*, 15, 24
- Hemoptysis, in bronchial malignancies, *April*, 14
- Hemorrhage, intracranial, coma in, *Aug.*, 21 f.
- Hemorrhagic fever, shock in, *Oct.*, 17, 37
- Hepatitis, toxic, from hydrazine derivatives, *Nov.*, 27
- Hepatitis, viral
complications and prognosis, *June*, 18 f.
differential diagnosis, *June*, 17 f.
fulminating, *June*, 11, 19, 23
immunity and cross-immunity, *June*, 21 f., 28 f.
infectious, *June*, 4, 5 ff.
control measures, *June*, 23 f.
epidemiology, *June*, 19 f.
incubation period, *June*, 4, 6, 11
routes of infectivity, *June*, 7 f., 20
pathology and course, *June*, 11 ff.
serum, *June*, 4, 25 ff.
epidemiology, *June*, 27 f.
etiology, *June*, 25 f.
incubation period, *June*, 4, 6, 26
onset and course, *June*, 26 f.
prevention, *June*, 4, 29 f.
transmission, *June*, 4, 27, 29
subacute, *June*, 11
treatment, *June*, 22 f.
- Heredity
of hemoglobins, *Feb.*, 3, 11 ff., 33
in Parkinsonism, *Jan.*, 5

Histoplasmosis, as solitary pulmonary nodule, *April*, 34
 Hutchinson-Gilford syndrome, *March*, 29
 Hyaline bodies, in Parkinsonism, *Jan.*, 8
 Hyaluronidase, role in sperm transport, *March*, 10
 Hydrazine derivatives, as stimulants, *Nov.*, 27 f.
 Hydroxyphenylpiperazine, as tranquilizer, *Nov.*, 21
 Hypertension, pulmonary, dyspnea in, *May*, 45
 Hyperventilation, *May*, 31 f.
 hypoxemia causing, *May*, 34 f.
 increased external ventilation causing, *May*, 32 ff.
 reflex, *May*, 39 ff.
 Hypochondriacs, tranquilizers for, *Nov.*, 12 f.
 Hypoglycemia, and coma, *Aug.*, 11, 15, 25 f.
 Hypogonadism, male, *March*, 3 ff.
 classification, *March*, 16
 of pituitary origin, *March*, 23 ff.
 prepubertal hypogonadotropic, *March*, 23
 of testicular origin, *March*, 17 ff.
 traumatic, *March*, 21
 treatment, *March*, 32 ff.
 Hypopituitarism, causing hypogonadism, *March*, 23 ff.
 Hypotension
 in comatose patient, *Aug.*, 15
 severe. *See Shock*
 Hypothalamus, disorders causing hypogonadism, *March*, 25
 Hypothermia, causing coma, *Aug.*, 30
 Hypothyroidism
 coma in, *Aug.*, 26
 induced in emphysema, *May*, 28
 Hypoxemia
 from alveolar-capillary block, *May*, 34 ff.
 causing hyperventilation, *May*, 34 ff.
 in emphysema, *May*, 27, 30
 from "lung shunts," *May*, 38 f.

I

Ileostomy, in colitis patients, *Sept.*, 25 f.

Imipramine, as stimulant, *July*, 30; *Nov.*, 28 f.

Infections

 causing shock, *Oct.*, 5 ff.
 classification of, *Oct.*, 8
 clinical manifestations, *Oct.*, 19 ff.
 treatment, *Oct.*, 34 ff.
 intracranial, coma in, *Aug.*, 23
 Infertility, male, *March*, 20 ff.
 treatment, *March*, 34
 Influenza
 shock in, *Oct.*, 15 f., 24, 31 f.
 Insomnia, drugs for, in suicidal patient, *July*, 32
 Iproniazid, as stimulant, *Nov.*, 25, 27

J

Jaundice, differential diagnosis, *June*, 17 f.

K

17-Ketosteroids, urinary, in normal male, *March*, 15
 Kidney, abnormalities in sickle cell disease, *Feb.*, 24
 Klinefelter's syndrome, *March*, 18 f.

L

Laurence-Moon-Biedl syndrome, *March*, 27 f.
 Lead poisoning, *Aug.*, 29
 Levarterenol
 in paroxysmal atrial tachycardia, *Dec.*, 18
 in shock, *Oct.*, 37 f.
 Life goals, and suicide risk, *July*, 19
 Life-situation
 change of, in therapy of suicide patient, *July*, 28
 and chronic anxiety, *Nov.*, 10 f.
 Liver
 disease, testicular atrophy in, *March*, 26
 failure, with shunt encephalopathy, *Aug.*, 24 f.
 in viral hepatitis
 function tests, *June*, 15 f., 22
 pathologic changes, *June*, 11
 Lobectomy, for malignant nodules, *April*, 22 f., 28, 31
 Lumbar puncture, in comatose patient, *Aug.*, 18

Lung
 alveolar-capillary block, *May*, 34 ff., 44
 chronic insufficiency leading to coma, *Aug.*, 23 f.
 function tests in dyspnea, *May*, 4, 45 f.
 inflammatory processes differentiated from solitary nodules, *April*, 35
 reduced compliance of dyspnea with, *May*, 7 f.
 and vital capacity, *May*, 13 ff.
 "shunt," hypoxemia in, *May*, 38 f.
 solitary nodule of, *April*, 3 ff.
 calcification in, *April*, 4, 5, 21 f.
 cavitation in, *April*, 21
 criteria for, *April*, 5
 diagnosis, *April*, 14 ff.
 growth and density in diagnosis, *April*, 20 f.
 incidence of malignancy in, *April*, 6 ff.
 metastatic malignancy in, *April*, 7 f., 15, 30 ff.
 satellite nodules, *April*, 21
 symptoms, *April*, 13 f.
 terms used for, *April*, 5 f.
 thoracotomy in diagnosis and treatment, *April*, 22 ff.
 vascular lesions, dyspnea in, *May*, 33
Lymphopathia venereum, *Sept.*, 17

M

Magnesium sulfate, in ventricular tachycardia, *Dec.*, 42
Malabsorption syndrome, in ulcerative colitis, *Sept.*, 11
Malaria, resistance to, and sickle cell trait, *Feb.*, 33
Male, adult
 climacteric in, *March*, 29
 normal laboratory values in, *March*, 15
 physical characteristics, *March*, 14
Malnutrition
 in colitis patients, *Sept.*, 19 f.
 effect on testicular function, *March*, 26 f.

Manganese powder, Parkinsonism due to, *Jan.*, 25
Mediastinum, tumors, causing dyspnea, *May*, 19
Meningococcemia
 clinical findings of shock in, *Oct.*, 22 f.
 pathogenesis of shock in, *Oct.*, 10
Meningoencephalitis, coma in, *Aug.*, 23
Meprobamate
 for depression, *July*, 31; *Nov.*, 29
 as stimulant, *Nov.*, 19, 29
Mesothelioma, pleural, differentiated from pulmonary nodule, *April*, 34 f.
Metabolism, effects of shock on, *Oct.*, 5 f.
Methemoglobinemia, hereditary, *Feb.*, 27 f.
Methylphenidate, for depressive states, *July*, 30; *Nov.*, 28
Methyltestosterone, for hypogonadism, *March*, 32 f.
Micrographia, in Parkinsonism, *Jan.*, 17
Mumps orchitis, *March*, 22
Muscle
 relaxants, as tranquilizers, *Nov.*, 19 f.
 respiratory
 fatigue causing dyspnea, *May*, 42 f.
 impairment, in decreased breathing capacity, *May*, 15
 paralysis, dyspnea in, *May*, 6, 21 f.
 in work of breathing, *May*, 13
 rigidity, in Parkinsonism, *Jan.*, 13 f., 16, 27 f.
 tone, diagnostic tests of, *Jan.*, 28 f.
Mutism, akinetic, *Aug.*, 12 f.
Mycoses
 shock in, *Oct.*, 32, 33
 in solitary pulmonary nodules, *April*, 33 f.
Myocarditis
 digitalis in, *Oct.*, 39
 in shock mechanism, *Oct.*, 15, 16, 18, 33

Myotonia dystrophica, testicular atrophy in, *March*, 28 f.
Myxedema, coma in, *Aug.*, 26

N

Nervous system
extrapyramidal complex diseases of, *Jan.*, 7
functional relations of, *Jan.*, 7 ff.
motor, in Parkinsonism, *Jan.*, 12 ff.
sensory, in Parkinsonism, *Jan.*, 18
surgery in Parkinsonism, *Jan.*, 35 ff.
Nitrous oxide anesthesia, and Parkinsonism, *Jan.*, 25
Nodule, solitary pulmonary. *See* Lung, solitary nodule of

O

Obstetrics
gram-negative infection following trauma in, *Oct.*, 20
postabortal clostridial septicemia, *Oct.*, 25
Oculogyric crisis, in Parkinsonism, *Jan.*, 22
Opiates, for colitis patients, *Sept.*, 22
Orchitis, mumps, *March*, 22
Oxygen
consumption
causes of abnormal increase, *May*, 13
in sickle cell hemoglobin diseases, *Feb.*, 20
therapy
for hypoxemia, *May*, 37
in infectious shock, *Oct.*, 39
in obstructive emphysema, *May*, 30
in restrictive respiratory insufficiency, *May*, 21
see also Respiration, artificial

P

Palsy, shaking. *See* Parkinsonism
Paralysis agitans. *See* Parkinsonism
Parasitic infections, mechanism of shock in, *Oct.*, 18 f.

Parkinsonism
arteriosclerotic, *Jan.*, 6, 24
pathologic changes in, *Jan.*, 10
clinical features and course, *Jan.*, 12 ff., 25 ff.
diagnostic tests, *Jan.*, 27 ff.
differential diagnosis, *Jan.*, 29 f.
drug therapy, *Jan.*, 31 ff., 37
experimental, *Jan.*, 11
idiopathic, *Jan.*, 6
incidence, *Jan.*, 4 f.
mental symptoms, *Jan.*, 19 f., 23, 26
pathologic physiology, *Jan.*, 10 ff.
pathology, *Jan.*, 7 ff.
physical therapy, *Jan.*, 33 f.
postencephalitic, *Jan.*, 6, 20 ff.
differentiated from paralysis agitans, *Jan.*, 21 f.
pathologic changes in, *Jan.*, 8 f.
surgical treatment, *Jan.*, 35 f.
syphilitic, *Jan.*, 24
Penicillin, fatal anaphylactic reaction to, *Oct.*, 34

Peptides
chain analysis in identification of hemoglobins, *Feb.*, 10 f.
genetic factors in polypeptide chain formation, *Feb.*, 13 ff.
of normal hemoglobins, *Feb.*, 8 f.
Pericarditis, cardiac tamponade in, *Oct.*, 33

Personality
in colitis patients, *Sept.*, 10
shift, and suicide danger, *July*, 22
Phenaglycodol, as stimulant, *Nov.*, 19
Phenothiazine derivatives, *Nov.*, 13, 14 ff.
for anxiety states, *July*, 31; *Nov.*, 14 ff.
choice and dosage, *Nov.*, 16 f.
side effects, *Nov.*, 16
Phenylephrine, in paroxysmal tachycardia, *Dec.*, 17

Phlebotomy
in advanced cardiopulmonary disease, *Aug.*, 24
in emphysema, *May*, 29
Physical therapy
in Parkinsonism, *Jan.*, 33 f.

- Physician
attitude of, in therapy of suicide
patient, *July*, 26, 28 f.
role in prevention of suicide, *July*,
5 f., 13 f.
- Pituitary
deficiency, in hypogonadism,
March, 23 f.
hormones, and testicular function,
March, 9 f., 12 f.
tumors, and hypogonadism,
March, 23 f.
- Plasma
transfusion in shock, *Oct.*, 37
in transmission of hepatitis, *June*,
4, 27, 30
- Pneumococcal infections, causing
shock, *Oct.*, 15
- Pneumonecctomy, for malignant pul-
monary nodules, *April*, 22 f.,
28
- Poisons, coma-producing, *Aug.*, 27
ff.
- Poliomyelitis, shock in, *Oct.*, 16 f.
- Posture, in Parkinsonism, *Jan.*, 17
- Potassium imbalance, with digitalis
toxicity, *Dec.*, 32, 34, 35
- Pregnancy, ulcerative colitis and,
Sept., 26
- Procaine amide
in paroxysmal atrial tachycardia
with block, *Dec.*, 35
in prevention of atrial tachycar-
dia, *Dec.*, 19
in ventricular tachycardia, *Dec.*,
40
- Proctitis, radiation, *Sept.*, 17
- Proctosigmoidoscopy, in colitis,
Sept., 13 f.
- Procyclidine, for Parkinsonism, *Jan.*,
32
- Prostigmine, in paroxysmal atrial
tachycardia, *Dec.*, 18
- Proteins
in hemoglobin, fingerprint analy-
sis, *Feb.*, 8 f.
serum, in sickle cell anemia, *Feb.*,
22 f.
- Pseudohermaphrodite, male, *March*,
17
- Psychic energizers, drugs as, *Nov.*, 7,
22 f.
- Psychoactive drugs, *Nov.*, 5 ff.
- Psychologic reactions, simulating
coma, *Aug.*, 12
- Psychoses
depressive types, *July*, 7 f.
states simulating coma, *Aug.*, 12
- Psychotherapy
in colitis patients, *Sept.*, 20 ff.
in Parkinsonism, *Jan.*, 34
for suicidal patient, *July*, 23 ff.
- Puberty
in normal male, *March*, 14
testicular development at, *March*,
5
- Pyrexia, effect on spermatogenesis,
March, 20
- Q
- Quinidine
for atrial fibrillation, *Dec.*, 23 f.
dosage schedules, *Dec.*, 25 f.
in prevention of atrial tachycar-
dia, *Dec.*, 19
in ventricular tachycardia,
Dec., 41, 42
- R
- Radiation, ionizing, testicular dam-
age from, *March*, 21
- Rauwolfia alkaloids, *Nov.*, 13, 17 ff.
choice and dosage, *Nov.*, 18 f.
mode of action, *Nov.*, 17 f.
side effects, *Nov.*, 18
- Reflexes, in Parkinsonism, *Jan.*, 18 f.
- Reserpine, as tranquilizer, *Nov.*, 17
f.
- Respiration, *See* Breathing, Muscles,
respiratory
- Respiration, artificial
as factor in shock, *Oct.*, 16 f.
mouth-to-mouth, with heart mas-
sage, *Dec.*, 43
- respirator therapy
in obstructive emphysema,
May, 29
in respiratory muscle paralysis,
May, 21 f.
- Rickettsial diseases, shock in, *Oct.*,
17 f.

Roentgenography
in pulmonary nodule diagnosis,
April, 17 ff.
notch sign, *April*, 18
tomography in, *April*, 21
in ulcerative colitis, *Sept.*, 14 f.
Rothmund's syndrome, *March*, 29

S

Salicylates, producing coma, *Aug.*,
29
Sarcoma, primary pulmonary, in
solitary nodule, *April*, 29 f.
Schistosomiasis, distinguished from
colitis, *Sept.*, 17
Scopolamine, for Parkinsonism,
Jan., 31
Seminal fluid, composition and func-
tion, *March*, 11 f.
Shock
anaphylactic, *Oct.*, 34
defined, *Oct.*, 6
hemorrhagic, bacterial factor in,
Oct., 10
infectious
cardiogenic, *Oct.*, 33
classification, *Oct.*, 8
clinical manifestations, *Oct.*,
19 ff.
endotoxic, *Oct.*, 7 ff., 19 ff.
pathogenesis, *Oct.*, 7
treatment measures, *Oct.*, 34 ff.
variability of, *Oct.*, 6
mechanisms of, *Oct.*, 7 ff.
nature of, *Oct.*, 5 f.
with ventricular tachycardia,
treatment, *Dec.*, 40, 41
Sialorrhea, in Parkinsonism, *Jan.*,
19, 23
Sickle cell disease. *See* Anemia,
sickle cell
Sickle cell trait
with hemoglobin C, *Feb.*, 12, 17
hemoglobins in, *Feb.*, 9, 10, 16
incidence of, *Feb.*, 25 f.
inheritance of, *Feb.*, 11 f.
population genetics, *Feb.*, 33
Sickling phenomenon, *Feb.*, 16 ff.
Skin
changes in Parkinsonism, *Jan.*, 23
tests, in solitary pulmonary nod-
ules, *April*, 16

Sleep
levels of, *Aug.*, 5
normal and abnormal, *Aug.*, 6
Speech
in depressive states, *July*, 10
in Parkinsonism, *Jan.*, 17 f.
laryngeal contact microphone
as aid to, *Jan.*, 34
Spermatozoa
development of, *March*, 5 f.
normal count, *March*, 15
transport to epididymis, *March*,
10
Spleen, in sickle cell disease, *Feb.*,
25, 26
Splenectomy, in hemoglobinopa-
thies, *Feb.*, 35 f.
Sputum examination, in solitary pul-
monary nodules, *April*, 16
Staphylococcal infections, shock in,
Oct., 13 f., 27 ff.
Steroid therapy
in diffuse pulmonary disease,
May, 37 f.
in fulminating hepatitis, *June*, 23
see also specific categories and
agents
Stimulants
choice of, *Nov.*, 27 ff.
compounds used in past as, *Nov.*,
24
conditions indicating use of, *Nov.*,
22 f.
modes of action, *Nov.*, 24 f.
Streptococcal infections, shock in,
Oct., 14, 30 f.
Streptolysin O, cardiotoxic effects,
Oct., 31
Stress
in etiology of Parkinsonism, *Jan.*,
6
intensity and patient response to,
in suicide risk, *July*, 17 ff.
Suicide
attempts
repetition of, *July*, 13
social element in, *July*, 4 f.
conscious preoccupation with,
July, 12 ff.
familial pattern in, *July*, 21
impending, detection and evalua-
tion of danger, *July*, 6 ff.

Suicide—(Cont.)

- impulsive behavior patterns and, *July*, 17
- incidence, *July*, 3 f.
- life-situation and patient response as factors, *July*, 17 ff.
- as magical solution to life-conflict, *July*, 20
- prevention
 - by detection of possibility, *July*, 6, 13 f., 16
 - hospitalization for, *July*, 33 ff.
 - pharmacotherapy in, *July*, 30 ff.
 - by psychiatric referral, *July*, 23
 - psychotherapy in, *July*, 25 ff.
 - role of physician, *July*, 5 f.
- reactivation in discharged hospital patients, *July*, 23, 34 f.
- Syphilis, cerebrovascular, causing Parkinsonism, *Jan.*, 24

T

Tachycardia

- atrial flutter, *Dec.*, 28 ff.
- nodal, *Dec.*, 36
- paroxysmal
 - atrial, *Dec.*, 8 ff.
 - atrial, with block, *Dec.*, 32 ff.
 - atrial fibrillation, *Dec.*, 20 ff.
- sinus (normal), *Dec.*, 8 ff.
- ventricular, *Dec.*, 36 ff.

Temperature, body

- and consciousness, *Aug.*, 17, 30
- effect on spermatogenesis, *March*, 20

Testes

- atrophy of, *March*, 18, 26, 27
- ductal obstruction, *March*, 21 f.
- embryology, *March*, 4 f.
- estrogens synthesized by, *March*, 8
- failure to develop, *March*, 17 ff.
- function
 - effect of estrogens on, *March*, 25 f.
 - and testosterone biosynthesis, *March*, 30
- hyperpyrexia of, *March*, 20
- morphology of, *March*, 3 ff.
- seminiferous-tubule - dysgenesis, *March*, 17 ff.

Testosterone

- defective production, effects, *March*, 30
- effect on male gonads, *March*, 26
- in treatment of hypogonadism, *March*, 32 f.

Thalassemia, *Feb.*, 14, 28 ff.

- hemoglobin abnormalities in, *Feb.*, 14 f.
- intermedia, *Feb.*, 29 f.
- therapy, *Feb.*, 35
- major, *Feb.*, 30 ff.
- therapy, *Feb.*, 35 f.
- minor, *Feb.*, 29

Thoracotomy, in pulmonary nodule diagnosis and treatment, *April*, 22 ff.

Thrombosis, vascular, in sickle cell disease, *Feb.*, 18, 20, 25

Thyrototoxicosis, atrial fibrillation in, *Dec.*, 27 f.

Trachea, obstruction of, *May*, 23, 24

Tracheostomy

- in decompensated respiratory insufficiency, *May*, 21
- tube causing dyspnea, *May*, 27

Tranquilizers

- affecting consciousness, *Aug.*, 29
- indications for, *July*, 31; *Nov.*, 7 ff., 12 f.
- mode of action, *Nov.*, 13 f.
- precursors of, *Nov.*, 6
- types of, *Nov.*, 14 ff., 19 f.

Transcyclopromine, as stimulant, *Nov.*, 29

Trauma

- as cause of coma, *Aug.*, 11, 17, 19
- obstetric, infection after, *Oct.*, 20

Tremor

- differential diagnosis, *Jan.*, 30
- of Parkinsonism, *Jan.*, 12 f.
- technics of measurement, *Jan.*, 28

Trihexyphenidyl, for Parkinsonism, *Jan.*, 31

Tuberculosis

- of colon, *Sept.*, 17
- in solitary pulmonary nodule, *April*, 15, 16

Tumors

- causing hypogonadism, *March*, 23, 25

insulin-producing, causing coma,
Aug., 26

intrapulmonary. *See* Lung, soli-
tary nodule of

Leydig cell, *March*, 6, 26

mediastinal, dyspnea due to, *May*,
19

Turner's syndrome, *March*, 19

U

Unconsciousness

levels of, *Aug.*, 4 f.

see also Coma

V

Virus

of infectious hepatitis, *June*, 4, 5
ff.

of serum hepatitis, *June*, 4, 6,
25 f.

W

Werner's syndrome, *March*, 29